HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Swisse’s Global Expansion Strategy Begins to Bear Fruit, Plots Move Into CBD

Executive Summary

Australian supplements brand Swisse is enjoying rapid growth in European and Asian markets. The brand's owner is now looking to tap into the growing demand for CBD with a range of new products slated for launch next year.

You may also be interested in...



China's Tightened E-Commerce Laws Lead To Plunging Profits At Blackmores

Changes to e-commerce laws in China have hit hard Australia's biggest dietary supplements player Blackmores. With sales and profits in China tumbling, the firm has had to rethink its strategy to reignite growth in the fiercely competitive market.

Swisse Wellness Eyes Global Expansion After Conquering China's Supplements Market

Having cemented leading positions in China and Australia, Swisse Wellness' owners H&H Group are looking to grow the reach of the premium supplements brand across Europe and Asia-Pacific. The firm is targeting 25% growth for Swisse this year after double-digit growth in 2018. 

Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories

Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel